These findings suggest that KYNA–HCAR3 interactions may activate distinct signaling and metabolic pathways, ultimately influencing cancer cell phenotypes and modulating their crosstalk with the tumor microenvironment. This evidence concerns the gene HCAR3 and neoplasm.